| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 54 | 2023 | 1018 | 7.960 |
Why?
|
| Acute Chest Syndrome | 8 | 2022 | 31 | 2.500 |
Why?
|
| Hydroxyurea | 14 | 2020 | 290 | 2.270 |
Why?
|
| Antisickling Agents | 10 | 2020 | 80 | 2.190 |
Why?
|
| Anemia, Sideroblastic | 10 | 2021 | 101 | 1.970 |
Why?
|
| Iron Overload | 6 | 2015 | 242 | 1.260 |
Why?
|
| Platelet Aggregation Inhibitors | 8 | 2022 | 3068 | 1.120 |
Why?
|
| Iron | 6 | 2018 | 1774 | 0.920 |
Why?
|
| beta-Thalassemia | 4 | 2018 | 225 | 0.900 |
Why?
|
| Anemia, Iron-Deficiency | 3 | 2018 | 365 | 0.890 |
Why?
|
| Iron Chelating Agents | 5 | 2018 | 139 | 0.780 |
Why?
|
| Pain | 10 | 2023 | 4986 | 0.740 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2021 | 154 | 0.730 |
Why?
|
| Genetic Diseases, X-Linked | 6 | 2018 | 372 | 0.630 |
Why?
|
| Erythrocyte Membrane | 1 | 2018 | 442 | 0.580 |
Why?
|
| Neonatal Screening | 2 | 2016 | 591 | 0.550 |
Why?
|
| Drugs, Investigational | 1 | 2018 | 214 | 0.550 |
Why?
|
| Iron Metabolism Disorders | 1 | 2014 | 27 | 0.490 |
Why?
|
| Hospitals, Pediatric | 4 | 2022 | 1775 | 0.490 |
Why?
|
| Serine Endopeptidases | 2 | 2018 | 1072 | 0.490 |
Why?
|
| Phlebotomy | 3 | 2015 | 141 | 0.480 |
Why?
|
| Fetal Hemoglobin | 3 | 2020 | 341 | 0.470 |
Why?
|
| Spherocytosis, Hereditary | 3 | 2019 | 80 | 0.430 |
Why?
|
| Docosahexaenoic Acids | 1 | 2018 | 875 | 0.410 |
Why?
|
| Child | 49 | 2023 | 77709 | 0.390 |
Why?
|
| Hemoglobin, Sickle | 3 | 2008 | 122 | 0.380 |
Why?
|
| Splenectomy | 3 | 2019 | 395 | 0.380 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2020 | 1344 | 0.380 |
Why?
|
| Analgesia, Patient-Controlled | 2 | 2023 | 109 | 0.380 |
Why?
|
| Vascular Diseases | 2 | 2016 | 1161 | 0.370 |
Why?
|
| Hemoglobins, Abnormal | 2 | 2007 | 119 | 0.360 |
Why?
|
| Mutation | 7 | 2021 | 29786 | 0.340 |
Why?
|
| Serratia Infections | 1 | 2008 | 7 | 0.340 |
Why?
|
| Genotype | 5 | 2021 | 12951 | 0.340 |
Why?
|
| Child, Preschool | 30 | 2021 | 41006 | 0.330 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 3 | 2016 | 361 | 0.300 |
Why?
|
| Cephalosporins | 1 | 2008 | 204 | 0.300 |
Why?
|
| Thrombasthenia | 1 | 2007 | 24 | 0.300 |
Why?
|
| Globins | 2 | 2007 | 415 | 0.300 |
Why?
|
| Adolescent | 40 | 2023 | 85781 | 0.280 |
Why?
|
| Phenotype | 6 | 2021 | 16365 | 0.280 |
Why?
|
| Glucuronosyltransferase | 2 | 2005 | 128 | 0.280 |
Why?
|
| Homeostasis | 3 | 2014 | 3340 | 0.270 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2007 | 142 | 0.260 |
Why?
|
| Humans | 91 | 2023 | 744343 | 0.250 |
Why?
|
| Anemia, Aplastic | 1 | 2007 | 226 | 0.250 |
Why?
|
| Chelation Therapy | 2 | 2013 | 67 | 0.250 |
Why?
|
| Blood Transfusion | 4 | 2018 | 1301 | 0.250 |
Why?
|
| Erythrocyte Transfusion | 4 | 2017 | 565 | 0.240 |
Why?
|
| Double-Blind Method | 5 | 2019 | 12026 | 0.240 |
Why?
|
| Bilirubin | 4 | 2017 | 425 | 0.240 |
Why?
|
| Cholelithiasis | 1 | 2005 | 414 | 0.230 |
Why?
|
| Neutropenia | 1 | 2008 | 895 | 0.230 |
Why?
|
| Clinical Protocols | 1 | 2009 | 1462 | 0.220 |
Why?
|
| Hemoglobins | 4 | 2018 | 1534 | 0.220 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2003 | 93 | 0.220 |
Why?
|
| Membrane Proteins | 2 | 2018 | 7880 | 0.220 |
Why?
|
| Male | 55 | 2021 | 350118 | 0.210 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2003 | 102 | 0.210 |
Why?
|
| Female | 55 | 2021 | 380194 | 0.210 |
Why?
|
| Hemoglobinopathies | 1 | 2002 | 96 | 0.200 |
Why?
|
| Data Collection | 1 | 2011 | 3341 | 0.200 |
Why?
|
| Anemia, Hemolytic, Congenital | 2 | 2014 | 69 | 0.200 |
Why?
|
| Indenes | 1 | 2021 | 57 | 0.190 |
Why?
|
| Granulocytes | 1 | 2003 | 548 | 0.190 |
Why?
|
| Polycythemia | 1 | 2021 | 126 | 0.190 |
Why?
|
| Mitochondrial Proteins | 2 | 2018 | 996 | 0.190 |
Why?
|
| Deferoxamine | 2 | 2018 | 151 | 0.190 |
Why?
|
| gamma-Globins | 1 | 2020 | 95 | 0.180 |
Why?
|
| Paraganglioma | 1 | 2021 | 143 | 0.180 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2020 | 45 | 0.180 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2014 | 547 | 0.180 |
Why?
|
| Ketamine | 2 | 2023 | 500 | 0.180 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2020 | 426 | 0.180 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2003 | 233 | 0.170 |
Why?
|
| Infant | 17 | 2021 | 35136 | 0.170 |
Why?
|
| Glycocalyx | 1 | 2020 | 88 | 0.170 |
Why?
|
| Surgical Wound Infection | 1 | 2008 | 1540 | 0.170 |
Why?
|
| Infant, Newborn | 11 | 2021 | 25625 | 0.170 |
Why?
|
| Benzoates | 3 | 2015 | 217 | 0.170 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 3 | 2015 | 292 | 0.170 |
Why?
|
| Tyrosine-tRNA Ligase | 1 | 2018 | 10 | 0.170 |
Why?
|
| Hydromorphone | 1 | 2019 | 65 | 0.160 |
Why?
|
| Bone Marrow Diseases | 1 | 2020 | 231 | 0.160 |
Why?
|
| Ankyrins | 2 | 2018 | 128 | 0.160 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2018 | 52 | 0.160 |
Why?
|
| MELAS Syndrome | 1 | 2018 | 50 | 0.160 |
Why?
|
| Analgesics, Opioid | 4 | 2023 | 3674 | 0.150 |
Why?
|
| Patient Readmission | 2 | 2011 | 3114 | 0.150 |
Why?
|
| Reticulocytosis | 1 | 2017 | 10 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 2 | 2020 | 1677 | 0.150 |
Why?
|
| Blood Component Removal | 1 | 2018 | 125 | 0.150 |
Why?
|
| Anemia, Neonatal | 1 | 2017 | 18 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2018 | 227 | 0.150 |
Why?
|
| Alu Elements | 1 | 2018 | 119 | 0.150 |
Why?
|
| Hemorrhage | 2 | 2022 | 3461 | 0.150 |
Why?
|
| Heterocyclic Compounds | 1 | 2018 | 249 | 0.150 |
Why?
|
| Pyruvate Metabolism, Inborn Errors | 1 | 2018 | 45 | 0.150 |
Why?
|
| Acidosis, Lactic | 1 | 2018 | 142 | 0.140 |
Why?
|
| Anemia, Hemolytic, Congenital Nonspherocytic | 1 | 2018 | 51 | 0.140 |
Why?
|
| Sickle Cell Trait | 2 | 2007 | 81 | 0.140 |
Why?
|
| Erythroblasts | 1 | 2016 | 150 | 0.140 |
Why?
|
| Fever | 2 | 2014 | 1616 | 0.140 |
Why?
|
| Germ-Line Mutation | 2 | 2018 | 1788 | 0.140 |
Why?
|
| Pyruvate Kinase | 1 | 2018 | 189 | 0.140 |
Why?
|
| Isoelectric Focusing | 1 | 2016 | 181 | 0.140 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2021 | 740 | 0.140 |
Why?
|
| Pediatrics | 1 | 2011 | 3475 | 0.140 |
Why?
|
| Mutagenesis, Insertional | 2 | 2018 | 655 | 0.140 |
Why?
|
| Polymorphism, Genetic | 2 | 2005 | 4328 | 0.130 |
Why?
|
| Molecular Chaperones | 1 | 2020 | 742 | 0.130 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1114 | 0.130 |
Why?
|
| Liberia | 1 | 2016 | 167 | 0.130 |
Why?
|
| Laboratories | 1 | 2019 | 463 | 0.130 |
Why?
|
| Stroke | 8 | 2015 | 9981 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 841 | 0.130 |
Why?
|
| Electron Transport Complex I | 1 | 2016 | 140 | 0.130 |
Why?
|
| Reticulocyte Count | 3 | 2017 | 37 | 0.130 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2010 | 362 | 0.130 |
Why?
|
| Platelet Function Tests | 1 | 2016 | 270 | 0.130 |
Why?
|
| Developmental Disabilities | 2 | 2014 | 1456 | 0.130 |
Why?
|
| Pain Measurement | 3 | 2021 | 3420 | 0.130 |
Why?
|
| Bronchodilator Agents | 1 | 2018 | 502 | 0.130 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 2133 | 0.130 |
Why?
|
| Triazoles | 3 | 2015 | 911 | 0.130 |
Why?
|
| Chromosomes, Human, X | 1 | 2016 | 296 | 0.130 |
Why?
|
| RNA Nucleotidyltransferases | 1 | 2014 | 64 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 2 | 2013 | 7181 | 0.120 |
Why?
|
| Morphine | 1 | 2019 | 657 | 0.120 |
Why?
|
| Blood Platelets | 2 | 2016 | 2508 | 0.120 |
Why?
|
| Secondary Prevention | 3 | 2014 | 1530 | 0.120 |
Why?
|
| GATA Transcription Factors | 1 | 2013 | 30 | 0.120 |
Why?
|
| Mutation, Missense | 3 | 2018 | 2564 | 0.120 |
Why?
|
| 5-Aminolevulinate Synthetase | 1 | 2013 | 57 | 0.120 |
Why?
|
| Heart Transplantation | 1 | 2007 | 3110 | 0.110 |
Why?
|
| Piperazines | 2 | 2015 | 2488 | 0.110 |
Why?
|
| Attitude to Health | 1 | 2022 | 2052 | 0.110 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 404 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 3 | 2009 | 7279 | 0.110 |
Why?
|
| Administration, Oral | 2 | 2015 | 3913 | 0.110 |
Why?
|
| DNA, Mitochondrial | 1 | 2018 | 817 | 0.110 |
Why?
|
| Base Sequence | 5 | 2018 | 12797 | 0.110 |
Why?
|
| Research Design | 3 | 2019 | 5987 | 0.110 |
Why?
|
| Familial Mediterranean Fever | 1 | 2013 | 61 | 0.110 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2015 | 550 | 0.110 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2018 | 3386 | 0.110 |
Why?
|
| Biological Assay | 1 | 2015 | 652 | 0.100 |
Why?
|
| Repressor Proteins | 2 | 2020 | 3023 | 0.100 |
Why?
|
| Sequence Deletion | 1 | 2016 | 1526 | 0.100 |
Why?
|
| RNA Interference | 1 | 2020 | 2889 | 0.100 |
Why?
|
| Young Adult | 16 | 2023 | 56430 | 0.100 |
Why?
|
| Hospitalization | 1 | 2011 | 10262 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 2 | 2012 | 892 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 10943 | 0.100 |
Why?
|
| Introns | 1 | 2013 | 991 | 0.100 |
Why?
|
| Lead Poisoning, Nervous System, Childhood | 1 | 2010 | 18 | 0.090 |
Why?
|
| Ferritins | 2 | 2021 | 590 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2016 | 956 | 0.090 |
Why?
|
| Postoperative Complications | 3 | 2014 | 15295 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 3 | 2020 | 1655 | 0.090 |
Why?
|
| Ion Transport | 1 | 2011 | 320 | 0.090 |
Why?
|
| Thiophenes | 1 | 2015 | 588 | 0.090 |
Why?
|
| Cerebral Arteries | 2 | 2010 | 494 | 0.090 |
Why?
|
| Treatment Outcome | 13 | 2019 | 63114 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2020 | 8324 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 9274 | 0.090 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2010 | 82 | 0.090 |
Why?
|
| Platelet Aggregation | 1 | 2013 | 798 | 0.090 |
Why?
|
| Hyperkalemia | 1 | 2011 | 218 | 0.090 |
Why?
|
| Thinness | 1 | 2013 | 480 | 0.090 |
Why?
|
| Platelet Activation | 1 | 2013 | 673 | 0.080 |
Why?
|
| Pia Mater | 1 | 2009 | 88 | 0.080 |
Why?
|
| Serratia marcescens | 1 | 2008 | 45 | 0.080 |
Why?
|
| Bone Marrow Cells | 1 | 2016 | 2513 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2022 | 3843 | 0.080 |
Why?
|
| Length of Stay | 3 | 2018 | 6309 | 0.080 |
Why?
|
| Pedigree | 4 | 2020 | 4644 | 0.080 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 503 | 0.080 |
Why?
|
| Hemoglobin E | 1 | 2007 | 6 | 0.080 |
Why?
|
| Urinalysis | 1 | 2010 | 369 | 0.080 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2007 | 56 | 0.080 |
Why?
|
| Syndrome | 3 | 2021 | 3251 | 0.080 |
Why?
|
| Retrospective Studies | 13 | 2023 | 77449 | 0.080 |
Why?
|
| Diagnosis, Differential | 4 | 2014 | 12959 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 1442 | 0.070 |
Why?
|
| Prognosis | 4 | 2018 | 29063 | 0.070 |
Why?
|
| Parvoviridae Infections | 1 | 2007 | 35 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 3 | 2020 | 5867 | 0.070 |
Why?
|
| Respiratory Tract Infections | 1 | 2014 | 961 | 0.070 |
Why?
|
| Middle East | 2 | 2018 | 219 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2020 | 3479 | 0.070 |
Why?
|
| Echoencephalography | 1 | 2007 | 135 | 0.070 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2013 | 1341 | 0.070 |
Why?
|
| B-Lymphocytes | 2 | 2013 | 4665 | 0.070 |
Why?
|
| Hematopoiesis | 1 | 2016 | 2072 | 0.070 |
Why?
|
| K562 Cells | 2 | 2020 | 634 | 0.070 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2007 | 60 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2017 | 2684 | 0.070 |
Why?
|
| Apoptosis | 1 | 2003 | 9727 | 0.070 |
Why?
|
| Cholecystitis | 1 | 2007 | 182 | 0.070 |
Why?
|
| Cerebral Revascularization | 1 | 2009 | 238 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2018 | 2063 | 0.070 |
Why?
|
| Blood Proteins | 1 | 2011 | 1124 | 0.070 |
Why?
|
| alpha-Thalassemia | 1 | 2006 | 46 | 0.070 |
Why?
|
| Bacteremia | 1 | 2013 | 962 | 0.070 |
Why?
|
| Self Report | 1 | 2017 | 3558 | 0.070 |
Why?
|
| Antigens, CD20 | 1 | 2007 | 199 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 9959 | 0.070 |
Why?
|
| Moyamoya Disease | 1 | 2009 | 238 | 0.070 |
Why?
|
| Adult | 14 | 2020 | 214055 | 0.070 |
Why?
|
| Thrombosis | 1 | 2020 | 2968 | 0.070 |
Why?
|
| Self Care | 1 | 2011 | 786 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2007 | 647 | 0.070 |
Why?
|
| Blood Flow Velocity | 3 | 2015 | 1423 | 0.070 |
Why?
|
| Liver | 2 | 2015 | 7474 | 0.060 |
Why?
|
| DNA Mutational Analysis | 3 | 2020 | 4186 | 0.060 |
Why?
|
| Vancomycin | 1 | 2008 | 501 | 0.060 |
Why?
|
| Cholecystectomy | 1 | 2007 | 395 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2018 | 10252 | 0.060 |
Why?
|
| Receptors, Purinergic P2Y12 | 2 | 2016 | 132 | 0.060 |
Why?
|
| Pleural Effusion | 1 | 2007 | 338 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2013 | 2107 | 0.060 |
Why?
|
| High-Throughput Screening Assays | 1 | 2010 | 944 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 693 | 0.060 |
Why?
|
| Drug Stability | 1 | 2004 | 291 | 0.060 |
Why?
|
| Solutions | 1 | 2004 | 426 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2016 | 5021 | 0.050 |
Why?
|
| Accidents, Traffic | 1 | 2008 | 819 | 0.050 |
Why?
|
| Incidence | 2 | 2016 | 20947 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2007 | 652 | 0.050 |
Why?
|
| Normetanephrine | 1 | 2021 | 26 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 4751 | 0.050 |
Why?
|
| Prednisone | 1 | 2007 | 1574 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2007 | 1850 | 0.050 |
Why?
|
| Spinal Fractures | 1 | 2008 | 696 | 0.050 |
Why?
|
| Erythrocytes | 1 | 2011 | 2455 | 0.050 |
Why?
|
| Recurrence | 2 | 2018 | 8340 | 0.050 |
Why?
|
| Overweight | 1 | 2013 | 2371 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 5853 | 0.050 |
Why?
|
| Hematologic Tests | 1 | 2002 | 240 | 0.050 |
Why?
|
| Models, Biological | 2 | 2015 | 9583 | 0.050 |
Why?
|
| Disease Management | 1 | 2012 | 2459 | 0.050 |
Why?
|
| Chromogranins | 1 | 2021 | 160 | 0.050 |
Why?
|
| Hemolysis | 1 | 2003 | 420 | 0.050 |
Why?
|
| Abdominal Pain | 1 | 2007 | 1063 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 1855 | 0.050 |
Why?
|
| Autistic Disorder | 1 | 2010 | 1185 | 0.050 |
Why?
|
| Heterozygote | 1 | 2007 | 2804 | 0.050 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2020 | 82 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 3768 | 0.050 |
Why?
|
| Survival Rate | 2 | 2012 | 12788 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2003 | 881 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 4933 | 0.050 |
Why?
|
| Biological Transport | 1 | 2004 | 2118 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2020 | 3505 | 0.040 |
Why?
|
| Prescriptions | 1 | 2022 | 387 | 0.040 |
Why?
|
| Spinal Fusion | 1 | 2008 | 1241 | 0.040 |
Why?
|
| Adrenal Glands | 1 | 2021 | 546 | 0.040 |
Why?
|
| Europe | 2 | 2017 | 3339 | 0.040 |
Why?
|
| Influenza, Human | 1 | 2010 | 1479 | 0.040 |
Why?
|
| Genetic Association Studies | 2 | 2018 | 2703 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2020 | 399 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2007 | 2035 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 3 | 2015 | 2731 | 0.040 |
Why?
|
| HLA-B7 Antigen | 1 | 1997 | 48 | 0.040 |
Why?
|
| Risk | 2 | 2013 | 9687 | 0.040 |
Why?
|
| Benzylamines | 1 | 2018 | 223 | 0.040 |
Why?
|
| Temperature | 1 | 2004 | 2206 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2007 | 1956 | 0.040 |
Why?
|
| Genes, MHC Class I | 1 | 1997 | 258 | 0.040 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 272 | 0.040 |
Why?
|
| Acute Disease | 1 | 2007 | 7149 | 0.040 |
Why?
|
| Plasma | 1 | 2020 | 575 | 0.040 |
Why?
|
| Bone Marrow Examination | 1 | 2016 | 157 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2016 | 114 | 0.030 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2016 | 125 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2020 | 798 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2003 | 1836 | 0.030 |
Why?
|
| Quality of Life | 1 | 2017 | 12804 | 0.030 |
Why?
|
| Patients | 1 | 2022 | 900 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 2124 | 0.030 |
Why?
|
| Computers, Handheld | 1 | 2017 | 208 | 0.030 |
Why?
|
| Africa | 1 | 2017 | 673 | 0.030 |
Why?
|
| Middle Aged | 7 | 2018 | 213383 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2010 | 6544 | 0.030 |
Why?
|
| Prevalence | 3 | 2021 | 15226 | 0.030 |
Why?
|
| Cardiomyopathies | 1 | 2007 | 1912 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 35421 | 0.030 |
Why?
|
| Risk Factors | 4 | 2021 | 72290 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 657 | 0.030 |
Why?
|
| Reticulocytes | 1 | 2014 | 290 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 1880 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2003 | 4217 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 1590 | 0.030 |
Why?
|
| Thymus Gland | 1 | 1998 | 1267 | 0.030 |
Why?
|
| Consensus | 1 | 2022 | 2959 | 0.030 |
Why?
|
| Boston | 2 | 2019 | 9313 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2020 | 3002 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2015 | 281 | 0.030 |
Why?
|
| Age Factors | 3 | 2017 | 18370 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2003 | 4026 | 0.030 |
Why?
|
| Point Mutation | 1 | 2018 | 1623 | 0.030 |
Why?
|
| RNA | 1 | 2003 | 2749 | 0.030 |
Why?
|
| Cell Survival | 1 | 2003 | 5882 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2011 | 39050 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2015 | 18111 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2016 | 498 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2003 | 2948 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2020 | 15519 | 0.030 |
Why?
|
| Time Factors | 3 | 2016 | 40075 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2022 | 1637 | 0.030 |
Why?
|
| Coronary Disease | 1 | 2007 | 6077 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 2013 | 425 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 1878 | 0.030 |
Why?
|
| Exons | 1 | 2018 | 2437 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2022 | 1643 | 0.030 |
Why?
|
| Cell Lineage | 2 | 2016 | 2504 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2011 | 190 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2016 | 2716 | 0.020 |
Why?
|
| Asthma | 1 | 2010 | 6011 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2020 | 3420 | 0.020 |
Why?
|
| Methylamines | 1 | 2011 | 123 | 0.020 |
Why?
|
| Mass Screening | 2 | 2021 | 5255 | 0.020 |
Why?
|
| Heart Defects, Congenital | 1 | 2007 | 4584 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1998 | 1838 | 0.020 |
Why?
|
| New England | 1 | 2013 | 1022 | 0.020 |
Why?
|
| Gene Expression | 1 | 2003 | 7799 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2013 | 40561 | 0.020 |
Why?
|
| Body Weight | 1 | 2020 | 4669 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2018 | 7729 | 0.020 |
Why?
|
| United States | 5 | 2018 | 69872 | 0.020 |
Why?
|
| Registries | 2 | 2015 | 8089 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1998 | 2540 | 0.020 |
Why?
|
| Zebrafish | 1 | 2020 | 2994 | 0.020 |
Why?
|
| Gallstones | 1 | 2011 | 286 | 0.020 |
Why?
|
| Multiple Organ Failure | 1 | 2011 | 390 | 0.020 |
Why?
|
| Binding Sites | 2 | 2013 | 6114 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2011 | 964 | 0.020 |
Why?
|
| Chelating Agents | 1 | 2010 | 380 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2003 | 9146 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2010 | 23338 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2020 | 14557 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2020 | 4456 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3920 | 0.020 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2013 | 770 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2022 | 3749 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 1107 | 0.020 |
Why?
|
| Immunoassay | 1 | 2010 | 752 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2007 | 11727 | 0.020 |
Why?
|
| Caregivers | 1 | 2017 | 2094 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 1344 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 1970 | 0.020 |
Why?
|
| Outpatients | 1 | 2013 | 1486 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2007 | 458 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 4204 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2018 | 5317 | 0.020 |
Why?
|
| Transgenes | 2 | 1998 | 1009 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1998 | 7722 | 0.020 |
Why?
|
| Physicians | 1 | 2022 | 4567 | 0.010 |
Why?
|
| Body Mass Index | 2 | 2013 | 12720 | 0.010 |
Why?
|
| Markov Chains | 1 | 2007 | 969 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2016 | 2957 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2011 | 5179 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8642 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2015 | 2151 | 0.010 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2010 | 981 | 0.010 |
Why?
|
| Alleles | 1 | 2014 | 6933 | 0.010 |
Why?
|
| Organ Specificity | 2 | 1998 | 2008 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2011 | 1170 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 1622 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2009 | 1486 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2013 | 2708 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 21827 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 4740 | 0.010 |
Why?
|
| Aged | 4 | 2016 | 163280 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2008 | 3846 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2007 | 1184 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 15076 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2016 | 19229 | 0.010 |
Why?
|
| Animals | 4 | 2020 | 168757 | 0.010 |
Why?
|
| Linear Models | 1 | 2010 | 5952 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1997 | 12072 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 12245 | 0.010 |
Why?
|
| Sex Factors | 1 | 2013 | 10397 | 0.010 |
Why?
|
| Mice | 3 | 2020 | 81183 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2021 | 23403 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2016 | 5442 | 0.010 |
Why?
|
| Logistic Models | 1 | 2013 | 13408 | 0.010 |
Why?
|
| Radiography | 1 | 2009 | 7023 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2009 | 2531 | 0.010 |
Why?
|
| Base Composition | 1 | 1997 | 293 | 0.010 |
Why?
|
| Antigens, Ly | 1 | 1998 | 291 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1998 | 1375 | 0.010 |
Why?
|
| Patient Selection | 1 | 2009 | 4215 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2010 | 5985 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2010 | 6256 | 0.010 |
Why?
|
| Hospitals | 1 | 2010 | 3952 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1998 | 1827 | 0.010 |
Why?
|
| Mice, Transgenic | 2 | 1998 | 9734 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2013 | 21746 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2009 | 3265 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1998 | 805 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1997 | 1202 | 0.010 |
Why?
|
| Embryonic Development | 1 | 1997 | 711 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 15540 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 19905 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 1997 | 1701 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 12261 | 0.010 |
Why?
|
| Obesity | 1 | 2013 | 12745 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1998 | 5974 | 0.000 |
Why?
|
| Brain | 1 | 2014 | 26385 | 0.000 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1998 | 3617 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1998 | 11483 | 0.000 |
Why?
|
| Pregnancy | 1 | 1997 | 29144 | 0.000 |
Why?
|